U.S. markets closed

OptiNose, Inc. (OPTN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.3300-0.1500 (-4.31%)
At close: 4:00PM EDT
3.3300 0.00 (0.00%)
After hours: 04:00PM EDT
Full screen
Loading interactive chart...
  • Experts Issue New Treatment Algorithm for Chronic Rhinosinusitis with Nasal Polyps That Highlights Role of XHANCE® In Stepwise Care
    PR Newswire

    Experts Issue New Treatment Algorithm for Chronic Rhinosinusitis with Nasal Polyps That Highlights Role of XHANCE® In Stepwise Care

    Optinose (NASDAQ:OPTN), a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists, today announced that the publication of a new stepped-care treatment algorithm in the International Forum of Allergy & Rhinology, "Multidisciplinary consensus on a stepwise treatment algorithm for management of chronic rhinosinusitis with nasal polyps," recommends Exhalation Delivery System-fluticasone (EDS-FLU) for the treatm

  • Optinose to Present at the Jefferies Virtual Healthcare Conference
    GlobeNewswire

    Optinose to Present at the Jefferies Virtual Healthcare Conference

    YARDLEY, Pa., June 01, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present a company overview and business update at the Jefferies Virtual Healthcare Conference on June 3, 2021, at 3:30 p.m. ET. To listen to a webcast of the presentation live, please visit the Investors page of the Optinose website. A replay of the webcast will be available for 30 days following the conclusion of the event. About OptinoseOptinose is a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. To learn more, please visit www.optinose.com or follow us on Twitter and LinkedIn. Optinose Investor ContactJonathan Neelyjonathan.neely@optinose.com 267.521.0531

  • OptiNose (OPTN) Reports Q1 Loss, Tops Revenue Estimates
    Zacks

    OptiNose (OPTN) Reports Q1 Loss, Tops Revenue Estimates

    OptiNose (OPTN) delivered earnings and revenue surprises of 5.77% and 4.90%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?